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Abstract. Chronic inflammation has been considered an 
important player in cancer proliferation and progression. High 
salt (sodium chloride) levels have been considered a potent 
inducer of chronic inflammation. In the present study, the 
synergistic role of high salt with interleukin (IL)-17 towards 
induction of the inflammatory and angiogenic stress factor 
vascular endothelial growth factor (VEGF)-A was investi-
gated. Stimulation of MCF-7 breast cancer cells with high salt 
(0.2 M NaCl) and sub-minimal IL-17 (1 ng/ml) enhanced the 
expression of VEGF-A (2.9 and 2.6-fold, respectively, P<0.05) 
compared with untreated cells. Furthermore, co-treatment 
with both high salt and sub-minimal IL-17 led to a 5.9-fold 
increase in VEGF-A expression (P<0.01), thus suggesting a 
synergistic role of these factors. VEGF-A promoter analysis 
and specific small interfering RNA knock-down of transcrip-
tion factors revealed that high salt induced VEGF-A expression 
through nuclear factor of activated T-cells (NFAT)5, while 
IL-17 induced VEGF-A expression via signal transducer and 
activator of transcription (STAT)3 signaling mechanisms. 
Treatment of normal human aortic endothelial cells with the 
supernatant of activated MCF-7 cells enhanced cell migration 
and induced expression of migration‑specific factors, including 
vascular cell adhesion protein, β1 integrin and cluster of 
differentiation 31. These data suggest that high salt levels 
synergize with pro-inflammatory IL-17 to potentially induce 
cancer progression and metastasis through VEGF-A expres-
sion. Therefore, low-salt diet, anti-NFAT5 and anti-STAT3 
therapies may provide novel avenues for enhanced efficiency 
of the current cancer therapy.
Introduction
A causal interlink between inflammation and cancer was first 
suggested in the 19th century by Rudolf Virchow (1). Accumu-
lating evidence over several decades has delineated underlying 
molecular mechanisms between chronic inflammation and 
cancer progression (2). Multiple studies have proposed that 
inflammation-induced genetic instability promotes tumor 
progression (2). Inflammation also causes defective immune 
surveillance and responses to anti-cancer chemotherapy (3). 
Chronic inflammation in the tumor microenvironment induces 
the production of free radicals such as reactive oxygen and 
nitrogen species, leading to oxidative damage and nitration of 
DNA bases, which increases the risk of cancer initiation (4). 
One of the key features of cancer progression and metastasis is 
markedly enhanced inflammatory stress factors in the tumor 
microenvironment (5).
One of the events linking inflammation and cancer is an 
increase in inflammatory cytokines, including tumor necrosis 
factor (TNF)α, interleukin (IL)-6 and IL-17, and stress growth 
factors such as vascular endothelial growth factor (VEGF), in 
the tumor microenvironment (6). The pro-tumorigenic role of 
IL-17, an inflammatory cytokine, has also been implicated in 
several types of cancer (7). In mice with carcinogen-induced 
skin tumors, deficient expression of IL-17 receptor resulted in 
a lower tumor incidence and a diminished tumor size (8). Typi-
cally, inflammatory cytokines induce their effect by activating 
inflammatory transcription factors such as the Janus kinase 
(JAK)/signal transducer and activator of transcription (STAT) 
signaling pathway (9). Along with cytokines, chronic inflam-
mation-induced stress molecules such as VEGF are known to 
be involved in cell proliferation, cell adhesion, inflammatory 
cell recruitment, angiogenesis and cell migration, leading to 
cancer progression (10). Specifically, the functions of VEGF in 
cancer are not limited to angiogenesis alone (11). VEGF-medi-
ated signaling occurs in tumor cells and is known to contribute 
to key aspects of tumorigenesis, including cancer initiation 
and progression through its interaction with specific receptors, 
leading to the regulation of trafficking and secretion of other 
chemokines and extracellular matrix proteins (11).
A wide variety of environmental and infectious agents 
have been attributed to increased risk of inflammation‑induced 
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cancer progression (12). Dietary high salt intake has been 
correlated with an increase in the incidence of cancers (13). 
Traditionally, high salt levels have been correlated with cardio-
vascular disease and inflammatory injury in arteries (14). In 
animal models, high sodium chloride levels have been demon-
strated to cause excessive inflammatory activation, triggering 
ischemia injury and end-organ stress mediated by reactive 
oxygen species and pro-inflammatory cytokine secretion, 
leading to irreversible cardiac cell damage (15,16). Importantly, 
in the context of breast cancer, the sodium content of mammary 
adenocarcinomas has been reported to be significantly higher 
than in the normal mammary epithelium (17). However, in 
that study, it was not clear if the increased sodium content 
observed was intracellular or extracellular. Human studies 
on gastric cancer suggested that excess sodium could cause 
inflammation and stomach ulcers, which could lead to gastric 
cancer (18). It is also important to understand that high sodium 
content in mammary adenocarcinomas has been shown to be 
significantly higher than that of normal lactating mammary 
epithelium (19). Furthermore, a correlation between expres-
sion of sodium symporters and increased invasion capacity 
of breast cancer has been previously suggested (20-22). In the 
present study, the synergistic effect of high sodium chloride 
levels with pro-inflammatory cytokines towards induction of 
the expression of VEGF-A, a crucial inflammatory and angio-
genic stress factor that is important in tumor progression and 
metastasis, is reported.
Materials and methods
Cell culture. The breast cancer cell line MCF-7 (HTB-22TM) 
and normal human aortic endothelial cells (NHAECs; 
PCS-100-011TM) were obtained from the American Type 
Culture Collection (ATCC; Manassas, VA, USA) and cultured 
in cell basal essential medium (30-2003; ATCC) along with 
the medium supplements recommended by the manufacturer. 
For stimulation studies, breast cancer cells were treated with 
varying concentrations (0-1,000 ng/ml) of IL-17 (Thermo 
Fisher Scientific, Inc., Waltham, MA, USA) or sodium chloride 
supplement (0.2 M final concentration; Sigma-Aldrich, St. 
Louis, MO, USA) for 48 h. It is important to note that sodium 
chloride concentration in regular cell culture basal medium 
is 0.1 M. Therefore, to perform high salt studies (0.2 M), the 
basal medium was supplemented with additional 0.1 M NaCl 
to achieve a final concentration of 0.2 M. Specific small inter-
fering (si)RNA (Santa Cruz Biotechnology, Inc., Dallas, TX, 
USA) mediated gene knock-down of STAT3 (sc-29493) and 
NFAT5 (sc-43968). The knock‑down efficiency was measured 
by reverse transcription-quantitative polymerase chain reaction 
(RT-qPCR), and non-specific siRNA (sc-37007) was used as a 
negative control. All experiments were performed in triplicate.
Western blot analysis. Western blot analysis was performed 
as described previously (23,24). All primary and secondary 
antibodies were obtained from Santa Cruz Biotechnology, 
Inc., unless mentioned otherwise. All primary antibodies were 
diluted to 1:200 and all secondary antibodies were diluted to 
1:1,000. The following specific primary antibodies against 
VEGF-A (sc-152), STAT3 (sc-482), STAT5 (sc-835), NFAT1 
(sc-7294), NFAT5 (sc-13035), vascular cell adhesion protein 
(VCAM; sc-8304), β1 integrin (sc-9970) and actin (sc-10731) 
were utilized. Phosphorylated proteins were probed with the 
phospho (p)-specific primary antibodies Ser-727-p-STAT3 
(sc-21876)  and Ser-155-p -N FAT5 (SAB4504718) 
(Sigma-Aldrich). The nitrocellulose membranes were 
developed using a chemiluminescence kit (EMD Millipore, 
Billerica, MA, USA) and analyzed using Universal Hood II 
(Bio-Rad Laboratories, Inc., Hercules, CA, USA). Densito-
metric analysis was performed using ChemiDoc XRS systems 
software provided by Bio-Rad Laboratories, Inc.
Messenger (m)RNA expression analysis. The expression 
profiles of intracellular signaling genes in MCF‑7 cells were 
analyzed using fluorescein amidite-labeled RT-qPCR primers 
for VEGF-A (Hs03929036_s1), NFAT5 (Hs00232437_m1), 
STAT3 (Hs01051722_s1), glyceraldehyde 3-phosphate dehy-
drogenase (GAPDH; Hs402869) and actin (Hs4333762T), 
which were obtained from Applied Biosystems (Thermo Fisher 
Scientific, Inc.), according to the manufacturer's protocol (25). 
Briefly, total RNA was extracted from 106 cells using TRIzol 
reagent (Sigma-Aldrich). RNA samples were quantified by 
their absorbance at 260 nm. The RNA was reverse transcribed, 
and qPCR was subsequently performed in a final reaction 
volume of 50 µl using LightCycler® 480 Probes Master 
(Roche Diagnostics, Indianapolis, IN, USA). Each sample 
was analyzed in triplicate. Cycling conditions consisted of an 
initial denaturation of 95˚C for 15 min, followed by 40 cycles 
of 95˚C for 30 sec, followed by annealing/extension at 61˚C 
for 1 min. Expression data were quantified using the 2-ΔΔCq 
method (26) and normalized to GAPDH expression.
Immunofluorescence microscopy. For staining of VEGF-A, 
50,000 MCF7 cells were grown on coverslips in 24-well 
plates (19). Cells were fixed with 4% paraformaldehyde (23). 
Normal 2% goat serum in Dulbecco's phosphate-buffered 
saline (Thermo Fisher Scientific, Inc.) with 1% bovine 
serum albumin (Sigma-Aldrich) and 0.1% Tween 20 was 
used for blocking and washing. The aforementioned specific 
anti-VEGF-A primary antibody and a phycoerythrin-conju-
gated antibody (cat no. 12-4739-81; eBioscience, Inc., San 
Diego, CA, USA) were used for immunofluorescence, with 
primary antibodies diluted to 1:10 and secondary antibodies 
diluted to 1:40. The images were captured using an Eclipse 
80i fluorescence microscope (Nikon Corporation, Tokyo, 
Japan) and processed using Metamorph version 6.3r2 software 
(Molecular Devices, LLC, Sunnyvale, CA, USA).
Plasmid constructs and luciferase reporter assay. For the 
reporter constructs, the VEGF-A promoter regions (-2,000 to 
+50 bp) were amplified from human genomic DNA (Zyagen, 
San Diego, CA, USA) by PCR using iProof™ High-Fidelity 
DNA Polymerase (Bio-Rad Laboratories, Inc.) (23). The PCR 
products were subcloned into the pGL4.11[luc2P] vector 
(Promega Corporation, Madison, WI, USA) upstream of a 
luciferase gene using appropriate restriction sites. Putative 
transcription factor binding sites were identified with the 
Transcription Element Search System (TESS) algorithm 
(http://www.cbil.upenn.edu/downloads/).
The transcription factor binding to the VEGF-A promoter 
was analyzed by luciferase assay as previously reported (20,23). 
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Briefly, MCF‑7 cells (1x105) were transfected in 24-well plates 
with 1 µg pGL4.11[luc2P] luciferase reporter vector driven by 
the VEGF-A promoter, or with 2 µg control vector. For trans-
fection of MCF-7 cells, 0.2x105 cells/well were seeded into 
a 24-well plate and grown for 24-48 h. Cells were harvested 
48 h post-transfection, and efficiency was measured by qPCR, 
immunostaining and western blotting.
C h ro m a t i n - i m m u n o p re c i p i t a t i o n  (C h I P)  a n d 
co‑immunoprecitation (Co‑IP). ChIP and Co-IP were 
performed as previously described (20). For ChIP analysis to 
identify the binding regions of NFAT5 and STAT3, ChIP-IT 
Express kit (Active Motif, Inc., Carlsbad, CA, USA) was utilized 
according to the manufacturer's protocol and as previously 
described (23). Control immunoglobulin (Ig)Gs, anti-NFAT5 
or anti-STAT3 (1 µg) were used to immunoprecipitate the 
DNA-protein complexes. Specific VEGF-A promoter regions 
were amplified using PCR and resolved on 2% agarose gels. 
PCR cycling conditions consisted of an initial denaturation 
step at 95˚C for 3 min, followed by 35 cycles of 95˚C for 30 sec, 
annealing at 60˚C for 30 sec and extension at 72˚C for 1 min. 
For NFAT5 and STAT3 Co-IP, proteins obtained from MCF-7 
cells were subjected to sodium dodecyl sulfate polyacrylamide 
gel electrophoresis (4-12% polyacrylamide gels) and immu-
noblotting. NFAT5 and STAT3 were detected with rabbit 
anti-NFAT5 and rabbit anti-STAT3 antibodies, respectively. 
The primary antibodies were diluted to 1:200 and secondary 
antibodies were diluted to 1:1,000
Enzyme-linked immunosorbent assay (ELISA). The secretory 
extracellular VEGF-A in the cell supernatant was quantitated 
by ELISA according to the manufacturer's protocol (R&D 
Systems, Inc., Minneapolis, MN, USA) (21). Due to the limi-
tation of the detection system, the supernatant was diluted 
1:1,000 and quantified with a standard curve using the manu-
facturer-provided standards. Detection of the optical density 
value at 450 nm was performed using EMax® Plus Microplate 
Reader (Molecular Devices, LLC), and data analysis was 
conducted using SoftMax Pro GxP software (version 5.4) 
provided by Molecular Devices, LLC.
Cell migration assay. The migratory ability of NHAECs 
following stimulation with the supernatant isolated from 
various MCF-7-experimental cell culture conditions was 
performed using Cultrex® Cell Migration Assays (cat 
no. 3465‑096‑K; R&D Systems, Inc.) according to the manufac-
turer's protocol. Briefly, serum‑starved NHAECs were placed 
in the top chamber, and fresh 24-h supernatant collected from 
MCF-7 cells that had been subjected to various experimental 
cell culture conditions was placed in the bottom chamber, sepa-
rated by a basement membrane-coated separation membrane. 
The migration ability was quantified following dissociation of 
the cells from the membrane with the appropriate dissociation 
buffers (provided in the Cultrex Cell Migration Assay) and 
colorimetrically analyzed at 595 nm.
Flow cytometry. The expression of cluster of differentiation 
(CD)31 on NHAECs was analyzed by flow cytometry using 
appropriated primary and fluorescein isothiocyanate-labelled 
secondary antibodies (25). Samples were analyzed using 
a FACSCalibur/LSR II flow cytometer (BD Biosciences, 
Franklin Lakes, NJ, USA), and cell sorting was performed 
with a FACSVantage cell sorter (BD Biosciences). Data 
were analyzed using FACSDiva™ software (version 8.0.1; 
BD Biosciences). Gates were set according to isotype controls.
Statistical analysis. Data were expressed as the mean ± stan-
dard error of the mean from four independent experiments. 
Statistical differences between the means were analyzed using 
a paired or unpaired Student's t test. P<0.05 was considered to 
indicate a statistically significant difference. All analyses were 
conducted using Origin version 7.0 (OriginLab, Northampton, 
MA, USA) or GraphPad version 5 software (GraphPad Soft-
ware, Inc., LaJolla, CA, USA).
Results
Enhanced expression of VEGF-A following co-stimulation 
of MCF‑7 cells with high sodium chloride and sub-minimal 
IL-17 levels. Although VEGF was initially considered to be a 
vascular permeability factor and an endothelial cell-specific 
mitogen, multiple lines of evidence convincingly suggest 
its critical role as an autocrine-signaling factor in solid 
tumors, including breast cancer (22). Previous studies have 
reported that IL-17 induces the expression of VEGF-A in 
solid tumors (27). In line with this evidence, preliminary 
experiments conduced by the present authors on MCF-7 breast 
cancer cells demonstrated a significantly higher expression of 
VEGF-A following stimulation with IL-17 at concentrations 
>100 ng/ml, but minimal response (<20%) at concentrations 
<10 ng/ml (data not shown). To determine the specific role 
of high sodium chloride levels (referred to as high salt) in a 
pro-inflammatory microenvironment, initial cell viability 
studies were performed, which demonstrated <30% cell 
viability at NaCl concentrations >0.25 M, while >95% cell 
viability was maintained at 0.15 and 0.2 M NaCl in the culture 
medium (data not shown). Therefore, in all the experiments 
described in the present study, 0.2 M NaCl was used for high 
salt condition, and 1 ng/ml IL-17 was used for sub-minimal 
IL-17 concentration.
As VEGF-A is a key inflammatory stress molecule 
and biomarker, experiments were performed in the present 
study to determine the role of high salt synergising with the 
pro-inflammatory cytokine effect of IL‑17 on the expression 
of VEGF-A protein. For that purpose, the breast cancer cell 
line MCF-7 was treated with either high salt (0.2 M NaCl), 
IL-17 (1 ng/ml) or a combination of both. As shown in Fig. 1A, 
western blot analysis of the cellular extract from MCF-7 cells 
demonstrated an increased expression of VEGF-A following 
co-treatment with high salt and sub-minimal IL-17. This was 
further verified by intracellular immunocytochemical staining 
of MCF-7 cells for VEGF-A (Fig. 1B). Quantitative mRNA 
analysis of VEGF-A (Fig. 1C) demonstrated that, under 
basal conditions, there was minimal expression of VEGF-A 
mRNA transcript (2.1±0.6-fold) compared with the GAPDH 
control transcript. However, following treatment with either 
high salt or sub-minimal IL-17 alone, there was a significant 
elevation of VEGF-A mRNA transcription (6.1±1.3 and 
5.4±0.8-fold, respectively, P<0.05). Co-treatment with both 
high salt and sub-minimal IL-17 demonstrated a 15.7±2.9-fold 
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increased VEGF-A transcript expression (P<0.05) over the 
basal conditions. These data were further confirmed by 
ELISA-based quantitative analysis of the supernatant from 
the aforementioned conditions to measure the secretion of 
VEGF-A protein by MCF-7 cells (Fig. 1D). Importantly, 
treatment with equimolar mannitol concentrations (0.1 M 
NaCl + 0.1 M mannitol) demonstrated no enhanced expres-
sion of VEGF-A (2.5±0.9-fold, P>0.70) over basal conditions. 
These data indicate that high salt and IL-17 exert a synergistic 
effect. Furthermore, as the synergistic effect was higher than 
the individual conditions alone, these results strongly suggest 
a possibility of two different signaling mechanisms separately 
induced by high salt and IL-17.
Transcription factors NFAT5 and STAT3 induce VEGF-A 
expression following co-stimulation with high salt and IL-17. 
Based on the aforementioned findings (Fig. 1), experiments 
were performed to determine the transcription factors involved 
in the signaling events mediated by high salt and IL-17 that 
led to increased expression of VEGF-A. The present authors 
previously demonstrated that STAT3 mediates IL-17-induced 
pro-inflammatory signaling (23). NFAT5, also known as 
tonicity-responsive enhancer binding protein (TonEBP), which 
is a mediator of osmotic stress and immune regulation, has also 
been observed to be upregulated in breast cancer (28). There-
fore, various transcription factors were initially analyzed by 
RT-qPCR, and NFAT5 and STAT3 demonstrated significantly 
enhanced expression following treatment with high salt and 
IL-17. The other transcription factors tested that did not induce 
a significant change under the current experimental conditions 
were NFAT1-4 and STAT1, -2, -4 and -6 (data not shown). 
Western blot and phosphoblot studies (Fig. 2A) demonstrated 
enhanced expression and phosphorylation of NFAT5 in MCF-7 
cells following treatment with high salt (0.2 M NaCl) for 
60 min, while stimulation with sub-minimal IL-17 (1 ng/ml) 
enhanced the expression and phosphorylation of STAT3. 
However, co-treatment with high salt and sub-minimal IL-17 
led to increased expression and phosphorylation of both NFAT5 
and STAT3. Quantitative analysis by RT-qPCR demonstrated 
that there was a 3.4-fold upregulation of total and phosphory-
lated NFAT5 (Fig. 2B and C) following treatment with high 
salt, which did not increase further upon co-treatment with 
both high salt and sub-minimal IL-17. Similarly, there was a 
3-fold upregulation in total and phosphorylated STAT3 levels 
(Fig. 2D and E) following treatment with sub-minimal IL-17, 
which did not increase further upon co-treatment with high 
salt and sub-minimal IL-17. These data support the earlier 
assertion that high salt and IL-17 potentially induce VEGF-A 
expression through two different signaling pathways.
To confirm that high salt and IL-17 induce separate 
signaling pathways that result in the induction of VEGF-A 
expression, siRNA knockdown experiments specific for 
NFAT5 and STAT3 were performed. Western blot analysis 
(Fig. 2F) demonstrated that siRNA knock-down of NFAT5 
and STAT3 individually, following co-treatment with high 
salt and sub-minimal IL-17, led to reduced intracellular 
expression of VEGF-A. As expected, combined knock-down 
of both NFAT5 and STAT3 synergistically diminished 
VEGF-A expression. This was further verified by immuno-
cytochemical analysis (Fig. 2G). Quantitative ELISA-based 
analysis of VEGF-A secretion (Fig. 2I) demonstrated 
that NFAT knock-down reduced VEGF expression to 
137±49 pg/ml, while STAT3 knock-down reduced VEGF 
expression to 152±41 pg/ml in high salt and sub-minimal 
IL-17-co-treated MCF-7 cells, where VEGF-A expression 
was 562±73 pg/ml prior to treatment. Taken together, these 
data confirm that high salt and IL-17 induce two different 
signaling mechanisms leading to enhanced expression of the 
inflammatory stress molecule VEGF-A.
NFAT5 and STAT3 bind to the VEGF-A promoter region at 
-1,471 and -840 bp upstream of the open reading frame. To 
determine the role of high salt and IL-17 in VEGF-A gene 
transcription, the luciferase reporter construct containing 
the -2,000 to +50 bp region of the human VEGF-A gene 
promoter was transfected into MCF-7 breast cancer cells. 
These luciferase-transfected cells were treated with either 
high salt, sub-minimal IL-17 or both, and luciferase activity 
was recorded. An increase in VEGF-A reporter activity was 
observed following individual stimulation with high salt 
(7.2-fold, Fig. 3A) and sub-minimal IL-17 (6.4-fold, Fig. 3B) 
over control null-luciferase vector-transfected cells. Further 
co-treatment with both high salt and sub-minimal IL-17 
produced a 25.2-fold increase (Fig. 3C) in luciferase activity 
compared with untreated cells. These data were in line with 
the results described in Fig. 2, thus supporting the hypoth-
esis that high salt and IL-17 work synergistically to enhance 
VEGF-A expression.
To specifically identify the putative DNA binding 
sequences for NFAT5 and STAT3 on the VEGF-A promoter, 
a computational analysis of the -2,000 to +50 bp region of 
the VEGF-A promoter was performed using TESS. This 
analysis identified two putative DNA binding sites for 
NFAT5 (TGGAAA at -1,471 and -1,809 bp) and two puta-
tive DNA binding sites for STAT3 (TTC CCA AA/TTT CCA 
AA at -840 and -622 bp) (Fig. 3A). To determine whether 
NFAT5 and STAT3 regulate VEGF-A expression in MCF-7 
cells, these cells were transfected with the mutant VEGF-A 
promoter reporter construct and treated with high salt, IL-17 
or both (Fig. 3A-C). As shown in Fig. 3A, following treat-
ment with high salt, the putative NFAT5 binding site mutant 
construct (*-1,474-73, GA to *TC) exhibited a significant 
decrease (≤66% loss of activity) in reporter activity compared 
with the native VEGF-A reporter activity. However, the other 
putative NFAT5 binding site mutant construct (*-1,812-11, 
GA to *TC) did not display any change in VEGF-A promoter 
activity, thus suggesting that the NFAT5 binding domain is 
located at -1,471 bp on the VEGF-A promoter. Similarly, 
following treatment with sub-minimal IL-17 (Fig. 3B), the 
putative STAT3 (TTC CCA AA or TTT CCA AA) binding 
mutant construct (*-843-842, CA to *TG) exhibited a signifi-
cant decrease (≤71% loss of activity) in reporter activity 
compared with the native VEGF-A reporter activity, while 
the other putative STAT3 binding mutant construct (*-625-24, 
CA to *TG) did not exhibit any change in VEGF-A promoter 
activity, thus suggesting that the putative STAT3 binding 
domain is located at -1,471 bp. As expected, these two 
mutants demonstrated the highest loss of activity following 
co-treatment with high salt and sub-minimal IL-17 (Fig. 3C), 
thus strongly suggesting a synergistic mechanism of action 
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between NFAT5 and STAT3 transcription factors in regu-
lating VEGF-A expression.
To determine whether NFAT5 and STAT3 bind to adja-
cent DNA binding sites on the VEGF-A promoter to form 
transcriptional-activation DNA-protein complexes, following 
high salt, IL-17 or combined treatment, MCF-7 cells were 
immunoprecipitated with anti-NFAT5, anti-STAT3 or control 
IgGs. The results of ChIP and PCR analysis using primers 
specific for the VEGF-A promoter regions -2,000 to -1,751 bp, 
-1,500 to -1,251 bp, -1,000 to -751 bp, -700 to -450 bp, and 
control primers for the -250 to +50 bp region of the actin 
promoter (Fig. 3E, black bars), demonstrated that NFAT5 
and STAT3 bind to the VEGF-A promoter at the -1,500 to 
-1,251 bp and -1,000 to -751 bp regions, respectively (Fig. 3D). 
The DNA binding pattern of NFAT5 and STAT3 strongly 
correlates with the locations of the consensus binding sites 
on the VEGF-A promoter determined by luciferase reporter 
activity (Fig. 3A-C). ChIP with control IgGs did not enrich 
VEGF-A promoter regions, demonstrating the specificity 
for these transcription factors. No binding was observed in 
PCRs conducted with primers specific for the -250 to +50 bp 
region of the actin promoter, which lacks these binding sites 
Figure 1. Induction of VEGF-A expression in MCF-7 breast cancer cells following stimulation with high salt and sub-minimal IL-17. (A) Western blot analysis 
of VEGF-A expression in MCF-7 cells following treatment with high salt (0.2 M NaCl), IL-17 (1 ng/ml) or both (0.2 M NaCl and 1 ng/ml IL-17). Of note, the 
regular complete medium used in the present study contained 0.1 M NaCl, and equimolar mannitol (0.1 M NaCl + 0.1 M mannitol) was used as a negative 
control. The cell lysates were probed with appropriate primary and secondary antibodies. (B) Immunocytostaining of MCF-7 cells for VEGF-A. VEGF-A 
was probed with rabbit anti-human primary antibody at 1:100, and later probed with phycoerythrin-conjugated goat anti-rabbit secondary antibody at 1:200. 
(C) VEGF-A messenger RNA expression was analyzed by reverse transcription-quantitative polymerase chain reaction. Quantitation was performed by the 
2−ΔΔCq method and normalized to glyceraldehyde 3-phosphate dehydrogenase expression. (D) Enzyme-linked immunosorbent assay-based analysis of VEGF-A 
in the supernatant of the MCF-7 cells following treatment with the conditions mentioned above. Data are represented as mean values ± standard error of the 
mean from four independent experiments. Statistical significance was analyzed with the Student's t test, *P<0.05; #P>0.05. VEGF, vascular endothelial growth 
factor; mRNA, messenger RNA; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; IL, interleukin.
  D  C
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(Fig. 3D). Furthermore, the protein-protein complexes were 
immunoprecipitated (Fig. 3E) and probed with anti-STAT3 
or anti-NFAT5 antibodies on western blotting. This supported 
the ChIP findings that NFAT5 and STAT3 were complexed 
together on the VEGF-A promoter. Taken together, these 
data clearly demonstrate that the transcription factors NFAT5 
Figure 2. NFAT5 and STAT3 transcription factors were induced in MCF-7 cells following stimulation with high salt and sub-minimal IL-17, respectively. 
(A) Western blot analysis was performed to determine the protein expression levels of NFAT5 (170 kDa), p-NFAT5 (170 kDa), NFAT1 (140 kDa), STAT3 
(86 kDa), p-STAT3 (86 kDa), STAT5 (92 kDa) and actin (43 kDa), both total and active phosphorylated forms, after 30 min of stimulation with high salt, 
sub-minimal IL-17 or both. Quantitative mRNA expression of (B) NFAT5, (C) STAT3, (D) p-NFAT5 and (E) p-STAT3 by RT-qPCR was analyzed after 60 min 
of stimulation with high salt, sub-minimal IL-17 or both. Quantitation was performed with the 2−ΔΔCq method normalized to GADPH expression. (F) Western 
blot analysis of VEGF-A expression in MCF-7 cells following stimulation with high salt and IL-17, along with NFAT5 and STAT3 knock-down by specific 
siRNA. Scrambled siRNA was used as negative control. Specific NFAT5 and STAT3-siRNA treatment resulted in decreased expression of NFAT5 and STAT3 
transcription factors, respectively. (G) Immunocytostaining of MCF-7 cells for VEGF-A following treatment with both high salt and sub-minimal IL-17, and 
specific siRNA knock‑down of NFAT5 and STAT3. (H) VEGF-A mRNA expression was analyzed by RT-qPCR in MCF-7 cells following stimulation with 
high salt and IL-17, along with NFAT5 and STAT3 knock-down by specific siRNA. Quantitation was performed with the 2−ΔΔCq method normalized to GADPH 
expression. (I) Enzyme-linked immunosorbent assay-based analysis of VEGF-A in the supernatant collected from MCF-7 cells following stimulation with 
high salt and IL-17, along with NFAT5 and STAT3 knock-down by specific siRNA. Data are represented as mean values ± standard error of the mean from four 
independent experiments. Statistical significance was analyzed by the Student's t test, *P<0.05; #P>0.05. VEGF, vascular endothelial growth factor; mRNA, 
messenger RNA; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; IL, interleukin; NFAT, nuclear factor of activated T-cells; STAT, signal transducer 
and activator of transcription; p-, phosphorylated; siRNA, small interfering RNA; RT-qPCR, reverse transcription-quantitative polymerase chain reaction.
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and STAT3 synergistically interact and are part of a larger 
transcription-regulatory complex enhancing the VEGF-A 
gene expression.
Enhanced cell migration following activation of NHAECs 
with VEGF-A supernatant. As VEGF-A has been impli-
cated in tumor cell migration, the potential upregulation 
of cell migration and surface proteins that mediate cell 
migration in NHAECs was determined (29). MCF-7 cells 
were pre-stimulated for 48 h with high salt, sub-minimal 
IL-17 or both, and later washed. Supernatant collected from 
24 h post-stimulation cultured cells under basal medium 
conditions was used to determine the migration efficiency 
of NHAECs. Cell migration was studied utilizing a migra-
tion chamber with NHAECs coated in the top chamber with 
serum-starved medium, while the bottom chamber was 
filled with supernatant collected from 24 h post-stimulated 
MCF-7 cells. As shown in Fig. 4A and B, following treat-
ment of NHAECs for 24 h with supernatant of MCF-7 cells 
subjected to combined pre-stimulation with high salt and 
IL-17, there was increased migration of NHAECs [optical 
density (OD), 0.62±0.19] compared with individual stimu-
lation with only high salt (OD, 0.28±0.09) or sub-minimal 
IL-17 (OD, 0.21±0.07). It is important to note that there was 
Figure 3. Binding sites of the transcription factors NFAT5 and STAT3 on the VEGF-A promoter to induce downstream gene transcription. (A) Transcription 
Element Search System-based computational analysis of -2,000 bp upstream of the VEGF-A open reading frame. Putative binding domains for NFAT5 and 
STAT3 at -1,809, -1,471, -840 and -622 bp were predicted to contain consensus sequences on the VEGF-A promoter. MCF-7 cells were transfected with a lucif-
erase reporter driven by constructs of the VEGF-A promoter (-2,000 to +50 bp; mutation *Δ-1,812-11 bp/-2,000 to +50 bp; and mutation *Δ-1,474-73 bp/-2,000 
to +50 bp) construct, and stimulated with high salt. (B) MCF-7 cells were transfected with luciferase reporters driven by constructs of the VEGF-A promoter 
(-2,000 to +50 bp; mutation *Δ-843-42 bp/-2,000 to +50 bp; and mutation *Δ-625-24 bp/-2,000 to +50 bp) construct, and stimulated with IL-17. (C) MCF-7 
cells were transfected with luciferase reporters driven by constructs of the VEGF-A promoter (-2,000 to +50 bp; mutation *Δ-1,474-73 bp/-2,000 to +50 bp; 
mutation *Δ-843-42 bp/-2,000 to +50 bp; or both mutations) construct, and stimulated with high salt and IL-17. Luciferase activity was measured 48 h after 
transfection and normalized to a Renilla luciferase internal control. The numbers indicate fold-change over the control vector. (D) VEGF-A promoter with 
binding sites for NFAT5 and STAT3. The four black horizontal bars represent the regions amplified by polymerase chain reaction with specific primers for the 
-2,000 to -1,751 bp, -1,500 to -1,251 bp, -1,000 to -751 bp and -700 to -450 bp regions of the VEGF-A promoter, and the negative control -250 to +50 bp region 
of the ACT1a promoter. Chromatin was immunoprecipitated with anti-NFAT5, anti-STAT3 or isotype control immunoglobulin G antibodies from MCF-7 
cells following stimulation with both high salt and IL-17. The first three lanes represent chromatin‑immunoprecipitation, while the fourth lane represents input 
chromatin. (E) Co-immunoprecitation of the protein-complex extracted by anti-STAT3 and anti-NFAT5 antibodies, and western blot analysis to probe with the 
opposite antibody (upper panel, probed with NFAT5 antibody and protein complex pulled-down with anti-STAT3 antibody; lower panel, probed with STAT3 
antibody and protein complex pulled-down with anti-NFAT5 antibody). Data are represented as mean values ± standard error of the mean from four indepen-
dent experiments. Statistical significance was analyzed with the Student's t test, *P<0.05; #P>0.05. Luc, luciferase; IL, interleukin; ACT1a, actin-1a; NFAT, 
nuclear factor of activated T-cells; STAT, signal transducer and activator of transcription; Ig, immunoglobulin; VEGF, vascular endothelial growth factor.
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a significant inhibition of NHAEC migration when blocked 
with anti-VEGF-A monoclonal IgG2b antibody (1:1,000 dilu-
tion; cat no. MAB293; R&D Systems) addition to the 
supernatant collected from high salt and IL-17-co-treated 
MCF-7 cells. This supports the hypothesis that cell migra-
tion was mediated by VEGF-A secreted from pre-stimulated 
MCF-7 cells. Furthermore, analysis of the expression of the 
migratory molecules VCAM (Fig. 4C), β1 integrin (Fig. 4D) 
and CD31 (Fig. 4E) demonstrated enhanced expression of 
these migratory molecules in NHAECs upon treatment with 
supernatant from pre-stimulated MCF-7 cells with both high 
salt and sub-minimal IL-17. These findings confirm that high 
salt synergised with the pro-inflammatory cytokine‑mediated 
expression of the stress factor VEGF-A.
Figure 4. Induction of cell migration and migration‑specific protein expression following activation of NHAECs with VEGF-A-rich supernatant. (A) Cell 
migration analysis after 24 h of culture in the migration chambers. The top chamber was coated with NHAECs placed in serum-starved medium. The lower 
chamber was filled with fresh 24‑h supernatant from MCF-7 cells following pre-stimulation for 48 h with high salt, IL-17 or both. To determine the specific 
role of VEGF-A, in the fifth panel, the lower chamber was filled with supernatant (as described above) with both high salt and IL-17, along with VEGF-A 
neutralization with immunoglobulin G2b monoclonal antibody at 1:1,000 dilution. (B) Optical density at 595 nm of the cells collected from the bottom 
chamber following 24 h of culture (C) Western blot analysis of NHAECs probed for VCAM (110 kDa) and β1 integrin (130 kDa) following treatment with 
supernatant from MCF-7 cells stimulated with high salt, IL-17 or both for 24 h. (D) Densitometry analysis of the western blotting results for VCAM normalized 
to basal expression. (E) Densitometry analysis of the western blotting results for β1 integrin normalized to basal expression. (F) Flow cytometry analysis of 
the expression of CD31 on NHAECs subjected to the stimulation conditions mentioned above. FL‑1 refers to the single fluorescence channel maintained for 
phosphatidylethanolamine-labeled probing of CD31. The isotype control is represented by the grey line, while CD31 is represented by the black line. Data are 
presented as mean values ± standard error of the mean from four independent experiments. Statistical significance was analyzed by the Student's t test, *P<0.05; 
#P>0.05. IL, interleukin; VEGF, vascular endothelial growth factor; mAb, monoclonal antibody; OD, optical density; AU, arbitrary unit; VCAM, vascular cell 
adhesion protein; CD, cluster of differentiation; NHAECs, normal human aortic endothelial cells.
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Discussion
Although high salt has been traditionally associated with 
cardiovascular diseases, recent evidence suggests that high 
salt levels also increase the risk of cancer (13). The tumor 
microenvironment is known to have high concentrations of 
several inflammatory cytokines, including IL-6, IL-17 and 
TNFα (30). High salt is a potent inducer of chronic inflam-
matory response through the activation of reactive oxygen and 
nitrogen species (31). Furthermore, chronic inflammation is 
considered a key initiator for several solid tumors, including 
breast cancer (2). As early as in the 1980s, high salt and sodium 
transporters in the tumor tissue were suggested to play a crit-
ical role in breast cancer progression and metastasis (17). More 
recently, a direct inflammatory effect of salt on immune cells 
such as T-cells and macrophages has been reported (32,33). 
However, the exact molecular mechanisms by which high salt 
induces inflammation in the tumor microenvironment are not 
yet defined.
The role of osmotic stress in inflammatory processes has 
been extensively suggested in the scientific literature (34). 
Culture of human peripheral blood cells under hyperosmotic 
conditions (330-410 mOsm/kg H2O) has been shown to induce 
expression of pro‑inflammatory cytokines such as IL-1 and 
IL-8 (35). Notably, patients with Crohn's disease, an inflam-
matory bowel disease, present with substantially higher 
osmolality of the faecal fluid compared with control subjects 
(490 vs. 340 mOsm/kg H2O), which strongly correlates with the 
intestinal histopathological score (36). In the tumor microen-
vironment, osmotic stress is considered to trigger receptor 
tyrosine kinases such as epidermal growth factor receptor, 
resulting in activation of the erbB-2/neu proto-oncogene (37). 
All the above lines of evidence suggest that hypernatremia 
or high sodium induce osmotic stress, which in-turn leads 
to an inflammatory response. The current study attempted 
to evaluate the direct inflammatory effect of high salt on 
hyperosmolarity-induced events (by performing control 
equimolar mannitol studies), in order to demonstrate that 
high salt in the cell microenvironment could directly induce 
expression of VEGF, a known inflammatory biomarker (10). 
However, the current results do not completely preclude a 
high salt-mediated, osmotic-stress-induced VEGF expression, 
which requires further studies.
Although VEGF was originally discovered as a vascular 
and endothelial-activating factor, several studies have conclu-
sively suggested its critical role in tumor cell progression 
and metastasis (10). Several isoforms of VEGF have been 
reported, including VEGF121, VEGF165 and VEGF189, (38). In 
addition, cell‑specific VEGF isoforms, including VEGF-A 
(present in the majority of cell types) (10), VEGF-B (present 
in neurons and retina) (39) and VEGF-C (present in macro-
phages) (40) have been reported. It is important to note that 
anti-VEGF monoclonal antibody-based therapeutic strategies 
are currently employed to treat cancers (41). It has also been 
suggested that direct stimulation of tumor cells by VEGF may 
inhibit apoptosis and increase their resistance to conventional 
chemotherapy and radiotherapy administered in cancer 
treatment (42). Therefore, understanding the mechanisms of 
expression of VEGF is crucial for anti-cancer therapeutic 
success. It has been well documented that VEGF exerts 
autocrine and paracrine pro-cancer effects in breast cancer 
through activation of cancer-specific AKT/phosphoinositide 
3-kinase signaling mechanisms (43). In the present study, the 
potential role of high salt in the presence of pro-inflammatory 
cytokines towards induction of VEGF has been investigated. 
Notably, the present results support the previous reports that 
inflammatory stimulus induces VEGF expression in MCF-7 
breast cancer cells (Fig. 1). Therefore, the present authors 
propose a novel role for high salt in the tumor microenvi-
ronment as an important mediator of VEGF expression. 
Furthermore, this expressed VEGF was observed to be critical 
for endothelial cell migration (Fig. 4). Taken together, the 
present data suggest that high salt plays a key inflammatory 
role in VEGF-mediated cancer cell proliferation.
The transcription factor NFAT5 is the most recently iden-
tified member of the NFAT family (44). Originally, NFAT5 
was termed TonEBP or osmotic response element-binding 
protein (34). In humans, previous studies addressing the func-
tion of NFAT5 were primarily focused on the kidney medulla, 
since renal cells are physiologically exposed to highly elevated 
interstitial osmolalities (34). NFAT5 is considered to exert 
an osmoprotective function in the kidney (33). However, a 
number of studies supported the notion that NFAT5 is impor-
tant in immune responses and lymphocyte activation (45). A 
recent study by Remo et al (28), utilizing in silico modeling 
and gene expression analysis on breast cancer patients (n=197), 
reported an enhanced expression of NFAT5 in inflammatory 
breast cancer. In line with that study, the present findings have 
demonstrated that high salt induces VEGF expression through 
specific upregulation of the transcription levels of NFAT5 
(Figs. 2 and 3), a known key molecule in breast cancer (27). In 
addition, the present study identified a putative NFAT5 binding 
domain on the VEGF-A promoter at -1,471 bp upstream of 
the VEGF-A coding gene (Fig. 3). These data clearly suggest 
that high salt mediates a direct inflammatory response in the 
cancer microenvironment.
The present study has demonstrated that high salt syner-
gises with IL-17, a pro-inflammatory cytokine, towards the 
expression of the inflammatory molecule VEGF-A (27). 
The role of IL-17 in cancer progression is well established. 
Several reports, including a previous study by the present 
authors, have demonstrated that IL-17 exerts its inflamma-
tory response through activation of the STAT3 transcription 
factor signaling pathway (23). STATs comprise a family 
of cytoplasmic transcription factors that mediate intracel-
lular signaling, which is usually generated by membrane 
receptor-ligand interactions (45). Numerous studies have 
demonstrated constitutive activation of STAT3 in a wide 
variety of human tumors (46). There is an increasing body of 
evidence suggesting that aberrant STAT3 signaling promotes 
initiation and progression of human cancers (46). Suppres-
sion of STAT3 activation has been reported to induce tumor 
cell death by apoptosis (45). In line with previous reports, 
the present authors have identified a putative STAT3 binding 
domain (Fig. 3) at -840 bp upstream of the VEGF-A coding 
gene. Furthermore, the results of the luciferase reporter assay 
conducted in the present study strongly suggest that high 
salt exerts its synergistic effect with the pro-inflammatory 
cytokine IL-17 through activation of two independent but 
synchronous signaling pathways via NFAT5 and STAT3, 
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in order to induce the expression of VEGF-A. However, the 
current study has limitations due to the experimental use and 
analysis of only one breast cancer cell line. Nonetheless, the 
authors consider that the conclusions of the present study are 
applicable to other solid tumors, which requires further vali-
dation in other tumor cell lines (particularly breast cancer), 
along with animal model studies.
In conclusion, in spite of significant advances, current 
anti-cancer therapies have a great scope for improvement (6). 
The current data suggest an important role for NFAT5 and 
STAT3 signaling in high salt-mediated cancer cell prolifera-
tion and migration. The authors propose a low-salt diet, and 
supplementing anti-VEGF therapy with anti-NFAT5 and 
anti-STAT3 therapies, as a future direction for efficient cancer 
therapy. However, further clinical and basic biomedical studies 
are required to validate these observations.
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